• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

5-羟色胺3受体拮抗剂不会改变可卡因引起的条件性位置偏爱,也不会改变大鼠伏隔核细胞外多巴胺水平的升高。

5-HT3 receptor antagonists do not modify cocaine place conditioning or the rise in extracellular dopamine in the nucleus accumbens of rats.

作者信息

Cervo L, Pozzi L, Samanin R

机构信息

Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.

出版信息

Pharmacol Biochem Behav. 1996 Sep;55(1):33-7. doi: 10.1016/0091-3057(96)00046-9.

DOI:10.1016/0091-3057(96)00046-9
PMID:8870035
Abstract

Three 5-HT3 receptor antagonists, MDL 72222, tropisetron, and ondansetron were studied for their ability to modify the conditioned place preference (CPP) induced by 10 mg/kg IP cocaine in rats. MDL 72222 (0.03-3 mg/kg SC) and tropisetron (0.01-0.1 mg/kg SC) administered, respectively, 30 min and 1 h before each conditioning session, did not affect the acquisition of cocaine CPP. Ondansetron (0.01-0.1 mg/kg SC) administered 30 min before each conditioning session or just before testing likewise had no effect. At 0.1 mg/kg SC ondansetron did not modify the increase of extracellular dopamine caused by 10 mg/kg cocaine in the nucleus accumbens. The results suggest that 5-HT3 receptor antagonists have no effect on the rewarding properties of cocaine or on the behaviour elicited by the stimuli previously associated with the drug's action.

摘要

研究了三种5-羟色胺3(5-HT3)受体拮抗剂MDL 72222、托烷司琼和昂丹司琼改变10mg/kg腹腔注射可卡因诱导的大鼠条件性位置偏爱(CPP)的能力。在每次条件训练前30分钟和1小时分别皮下注射MDL 72222(0.03 - 3mg/kg)和托烷司琼(0.01 - 0.1mg/kg),不影响可卡因CPP的获得。在每次条件训练前30分钟或测试前即刻皮下注射昂丹司琼(0.01 - 0.1mg/kg)同样无效。皮下注射0.1mg/kg昂丹司琼不改变10mg/kg可卡因引起的伏隔核细胞外多巴胺增加。结果表明,5-HT3受体拮抗剂对可卡因的奖赏特性或先前与药物作用相关的刺激所引发的行为无影响。

相似文献

1
5-HT3 receptor antagonists do not modify cocaine place conditioning or the rise in extracellular dopamine in the nucleus accumbens of rats.5-羟色胺3受体拮抗剂不会改变可卡因引起的条件性位置偏爱,也不会改变大鼠伏隔核细胞外多巴胺水平的升高。
Pharmacol Biochem Behav. 1996 Sep;55(1):33-7. doi: 10.1016/0091-3057(96)00046-9.
2
Differential effects of ondansetron and alpha-flupenthixol on responding for conditioned reward.昂丹司琼和α-氟哌噻吨对条件性奖赏反应的不同影响。
Psychopharmacology (Berl). 1997 Nov;134(1):64-72. doi: 10.1007/s002130050426.
3
5-HT3 receptor antagonist MDL 72222 attenuates cocaine- and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the rat.5-羟色胺3受体拮抗剂MDL 72222可减弱可卡因和吗茚酮对大鼠的神经化学及行为学影响,但对哌甲酯无此作用。
Psychopharmacology (Berl). 2002 Feb;159(4):341-50. doi: 10.1007/s00213-001-0939-4. Epub 2001 Nov 23.
4
Blockade of accumbens 5-HT3 receptor down-regulation by ondansetron administered during continuous cocaine administration.
Eur J Pharmacol. 1999 Jan 8;364(2-3):79-87. doi: 10.1016/s0014-2999(98)00795-x.
5
Adolescents differ from adults in cocaine conditioned place preference and cocaine-induced dopamine in the nucleus accumbens septi.青少年在可卡因条件性位置偏爱以及伏隔核中可卡因诱导的多巴胺方面与成年人不同。
Eur J Pharmacol. 2006 Nov 21;550(1-3):95-106. doi: 10.1016/j.ejphar.2006.08.034. Epub 2006 Aug 26.
6
5HT3 receptor antagonists do not block nicotine induced hyperactivity in rats.
Psychopharmacology (Berl). 1995 May;119(2):213-21. doi: 10.1007/BF02246163.
7
5-HT3 receptor antagonist MDL 72222 dose-dependently attenuates cocaine- and amphetamine-induced elevations of extracellular dopamine in the nucleus accumbens and the dorsal striatum.
Pharmacol Toxicol. 1996 May;78(5):317-21. doi: 10.1111/j.1600-0773.1996.tb01382.x.
8
The 5-HT3 antagonist zacopride attenuates cocaine-induced increases in extracellular dopamine in rat nucleus accumbens.5-羟色胺3受体拮抗剂扎考必利可减弱可卡因引起的大鼠伏隔核细胞外多巴胺水平升高。
Pharmacol Biochem Behav. 1993 Aug;45(4):759-63. doi: 10.1016/0091-3057(93)90118-d.
9
In vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum.体内证据表明,5-羟色胺2C受体拮抗剂而非激动剂可调节可卡因诱导的大鼠伏隔核和纹状体中的多巴胺释放。
Neuropsychopharmacology. 2004 Feb;29(2):319-26. doi: 10.1038/sj.npp.1300329.
10
Neurokinin 3 receptor activation potentiates the psychomotor and nucleus accumbens dopamine response to cocaine, but not its place conditioning effects.神经激肽3受体激活增强了精神运动和伏隔核多巴胺对可卡因的反应,但不影响其位置条件作用效应。
Eur J Neurosci. 2007 Apr;25(8):2457-72. doi: 10.1111/j.1460-9568.2007.05491.x.

引用本文的文献

1
Role of serotonin in central dopamine dysfunction.血清素在中枢多巴胺功能障碍中的作用。
CNS Neurosci Ther. 2010 Jun;16(3):179-94. doi: 10.1111/j.1755-5949.2010.00135.x.
2
The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy.5-羟色胺3受体在药物滥用中的作用以及作为药物治疗靶点的作用。
CNS Neurol Disord Drug Targets. 2008 Nov;7(5):454-67. doi: 10.2174/187152708786927886.
3
Prenatal exposure to cocaine alters the development of conditioned place-preference to cocaine in adult mice.孕期接触可卡因会改变成年小鼠对可卡因条件性位置偏好的发展。
Pharmacol Biochem Behav. 2007 Oct;87(4):462-71. doi: 10.1016/j.pbb.2007.06.002. Epub 2007 Jun 21.
4
Effects of quipazine and m-chlorophenylbiguanide (m-CPBG) on temporal differentiation: evidence for the involvement of 5-HT2A but not 5-HT3 receptors in interval timing behaviour.喹哌嗪和间氯苯双胍(m-CPBG)对时间辨别能力的影响:5-HT2A受体而非5-HT3受体参与间隔计时行为的证据。
Psychopharmacology (Berl). 2005 Sep;181(2):289-98. doi: 10.1007/s00213-005-2233-3. Epub 2005 Oct 14.
5
Agents in development for the management of cocaine abuse.正在研发用于治疗可卡因滥用的药物。
Drugs. 2004;64(14):1547-73. doi: 10.2165/00003495-200464140-00004.
6
Involvement of 5-HT(3) receptors in the nucleus accumbens in the potentiation of cocaine-induced behaviours in the rat.伏隔核中5-羟色胺(3)受体参与可卡因诱导的大鼠行为增强作用。
Br J Pharmacol. 2000 Dec;131(7):1294-302. doi: 10.1038/sj.bjp.0703687.
7
Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors.电刺激大鼠中缝背核后伏隔核与纹状体中多巴胺释放的相反变化:5-羟色胺3受体的作用
J Neurosci. 1998 Aug 15;18(16):6528-38. doi: 10.1523/JNEUROSCI.18-16-06528.1998.